Trial Profile
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 26 Mar 2023
Price :
$35
*
At a glance
- Drugs Sparsentan (Primary) ; Irbesartan
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms DUET
- Sponsors Travere Therapeutics
- 23 Mar 2023 According to Travere Therapeutics media release, data from open-label extension part of this study will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2 (ISN-WCN), and NKF Spring Clinical Meetings in Austin, TX
- 26 Oct 2022 According to Travere Therapeutics media release, data from this study will be presented at the American Society of Nephrology (ASN) Kidney Week 2022
- 21 Apr 2022 Planned End Date changed from 1 Aug 2023 to 1 Feb 2026.